Prolong Pharmaceuticals

Prolong Pharmaceuticals company information, Employees & Contact Information

Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC is developing products to treat several diseases and their debilitating comorbidities which cause reduced quality of life, increased medical costs and significant mortality. Comorbidities are a common consequence of sickle cell disease, chemotherapy, atherosclerosis, diabetes and many other diseases. - The company's lead product, SANGUINATE™, is focused on treating the comorbidities of sickle cell disease and hemorrhagic stroke - Prolong has a long-acting 3rd generation biologic in clinical development for the treatment of anemia, a comorbidity common with chronic kidney disease and cancer chemotherapy - Other products are also in development for comorbidities that result from diseases such as cardiovascular disorders and cancer ___________

Company Details

Employees
20
Founded
-
Address
300b Corporate Court, South Plainfield,new Jersey 07080,united States
Phone
908-444-4660
Email
in****@****rma.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
South Plainfield, New Jersey
Looking for a particular Prolong Pharmaceuticals employee's phone or email?

Prolong Pharmaceuticals Questions

News

Prolong Pharmaceuticals to Present Clinical Data regarding PP-007, PEGylated carboxyhemoglobin bovine product, at the 2024 International Symposium on Blood Substitutes (ISBS) - Business Wire

Prolong Pharmaceuticals to Present Clinical Data regarding PP-007, PEGylated carboxyhemoglobin bovine product, at the 2024 International Symposium on Blood Substitutes (ISBS) Business Wire

Prolong Pharmaceuticals to Present Phase 1/2 Data from HEMERA-1 for PP-007 in Acute Ischemic Stroke (AIS) at the 2025 World Stroke Conference (WSC) - The AI Journal

Prolong Pharmaceuticals to Present Phase 1/2 Data from HEMERA-1 for PP-007 in Acute Ischemic Stroke (AIS) at the 2025 World Stroke Conference (WSC) The AI Journal

U.S. Food and Drug Administration (FDA) Grants Prolong Pharmaceuticals FDA Fast Track Designation for Novel Stroke Therapy (PP-007) in HEMERA-1 Clinical Study - Business Wire

U.S. Food and Drug Administration (FDA) Grants Prolong Pharmaceuticals FDA Fast Track Designation for Novel Stroke Therapy (PP-007) in HEMERA-1 Clinical Study Business Wire

Prolong Pharmaceuticals to Present Preliminary Phase 1 Data from HEMERA-1 for PP-007 in Acute Ischemic Stroke (AIS) at the 2025 International Stroke Conference (ISC) - Business Wire

Prolong Pharmaceuticals to Present Preliminary Phase 1 Data from HEMERA-1 for PP-007 in Acute Ischemic Stroke (AIS) at the 2025 International Stroke Conference (ISC) Business Wire

Prolong Pharmaceuticals Announces Presentation of Phase 1 Data from HEMERA-1 Clinical Study of PP-007 in Patients with Acute Ischemic Stroke at the Late-Breaking Science Session, ISC 2023 - Business Wire

Prolong Pharmaceuticals Announces Presentation of Phase 1 Data from HEMERA-1 Clinical Study of PP-007 in Patients with Acute Ischemic Stroke at the Late-Breaking Science Session, ISC 2023 Business Wire

Top Prolong Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant